Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 71335-2093

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 71335-2093). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)
A line graph depicting the mean change from baseline in ADAS-cog scores over 30 weeks of treatment. It compares Donepezil Hydrochloride at 10 mg/day and 5 mg/day doses versus placebo. The vertical axis shows clinical improvement and decline, while the horizontal axis represents weeks of drug treatment.*
FDA Label Image

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)
A cumulative percentage plot comparing Donepezil Hydrochloride 10 mg/day with placebo over ADCS-ADL change from baseline. The x-axis represents ADCS-ADL change scores from +20 to -20, and the y-axis shows the cumulative percentage of patients from 0 to 100%. Two curves show patient response distributions for donepezil (black circles) and placebo (open squares).*
FDA Label Image

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)
A line graph comparing SIB (Severe Impairment Battery) change from baseline over 24 weeks of drug treatment with Donepezil Hydrochloride at doses of 10 mg/day and 23 mg/day. The x-axis represents weeks, and the y-axis shows the LS mean change from baseline with error bars. The graph indicates clinical improvement above baseline and clinical decline below baseline.*
FDA Label Image

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)
A cumulative percentage of patients graph showing SIB (Severe Impairment Battery) change from baseline for Donepezil Hydrochloride at doses of 23 mg/day and 10 mg/day. The X-axis represents the SIB change from baseline ranging from positive to negative values, and the Y-axis shows the cumulative percentage of patients from 0 to 100%. Two curves compare patient response distributions for the two dosages.*
FDA Label Image

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)
Bar graph comparing percentages of patients across CIBIC-plus rating categories for Donepezil Hydrochloride at 10 mg/day and 23 mg/day dosages. Categories include Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse, with the highest percentage in the No Change category for both doses.*
FDA Label Image

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)
A cumulative percentage graph depicting change from baseline in ADAS-cog scores for patients treated with placebo, Donepezil Hydrochloride 5 mg, and Donepezil Hydrochloride 10 mg. The x-axis represents change from baseline ranging from -15 to 15, and the y-axis shows cumulative percentage of patients from 0 to 100. The graph includes lines for each treatment group and a small table of ADAS-cog change percentages at various points for each group.*
FDA Label Image

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)
A bar chart comparing the percentage of patients by CIBIC-plus rating categories for Donepezil Hydrochloride at doses 10 mg/day, 5 mg/day, and placebo. Ratings range from markedly improved to markedly worse, showing patient outcomes distribution under different treatments.*
FDA Label Image

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)
A line graph showing ADAS-cog change from baseline (mean ± SE) over 15 weeks of drug treatment. It compares Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and placebo. The y-axis indicates clinical improvement or decline, with baseline at zero. The x-axis shows weeks of drug treatment, including a placebo period starting after week 12.*
FDA Label Image

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)
A cumulative percentage of patients chart showing the change from baseline on the x-axis and cumulative percentage on the y-axis. It compares Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo groups with labeled points at 7 points, 4 points, and no change. The graph includes a table summarizing the percentage of patients with changes in ADAS-cog scores of -7, -4, and 0 for each treatment group.*
FDA Label Image

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)
A bar chart showing the distribution of patient outcomes based on the CIBIC-plus Rating for Donepezil Hydrochloride at 10 mg/day, 5 mg/day, and placebo groups. The x-axis categorizes patient improvements from 'Markedly Improved' to 'Markedly Worse,' while the y-axis represents the percentage of patients within each category.*
FDA Label Image

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)
A line graph depicting the SIB change from baseline (Mean ± SE) over 6 months of drug treatment comparing Donepezil Hydrochloride 10 mg/day and placebo. The graph shows clinical improvement trends with Donepezil and clinical decline with placebo over the treatment period.*
FDA Label Image

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)
A cumulative percentage graph comparing the change in SIB (Severe Impairment Battery) scores from baseline between Donepezil Hydrochloride 10 mg/day and placebo groups in patients. The x-axis represents SIB change from baseline, and the y-axis represents the cumulative percentage of patients, showing higher cumulative improvement in the Donepezil group.*
FDA Label Image

Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)

Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)
A line graph showing the mean change from baseline in ADCS-ADL scores over 6 months of drug treatment. The graph compares Donepezil Hydrochloride 10 mg/day with placebo, illustrating clinical improvement versus clinical decline on the vertical axis and months of treatment on the horizontal axis.*
FDA Label Image

Chemical Structure (Donepezil Str)

Chemical Structure (Donepezil Str)
Chemical structure of Donepezil Hydrochloride showing its molecular arrangement including aromatic rings, methoxy groups, and piperidine moiety, along with the associated hydrochloride (HCl) component.*
FDA Label Image

Label (Lbl713352093)

Label (Lbl713352093)
Label for Donepezil 5 mg tablet, film coated, oral dosage form, labeled under Bryant Ranch Prepack. The label includes a comparison to Aricept 5 mg tablet by Rising Pharma Holdings Inc. It specifies a package size of 90 tablets and storage instructions at 20°-25°C (68°-77°F). The label also warns to keep all drugs out of reach of children and indicates the product is Rx only. NDC 71335-2093 is shown along with a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.